Immunic (NASDAQ:IMUX) Research Coverage Started at Brookline

Investment analysts at Brookline Capital Management began coverage on shares of Immunic (NASDAQ:IMUX – Get Free Report) in a research report issued to clients and investors on Friday, Benzinga reports. The firm set a “buy” rating and a $10.00 price target on the stock. Separately, StockNews.com downgraded shares of Immunic from a “hold” rating to […]

Related Keywords

Germany , United States , , Northern Trust Corp , Immunic Company Profile , Jpmorgan Chase Co , Immunic Inc , Nasdaq , Blackrock Inc , Brookline Capital Management , Get Free Report , Trust Corp , Two Sigma Investments , Sigma Investments , Immunic Daily ,